Drug intelligence / Profile preview

DW-330SR2

Development stage: Phase 3
Lead developer: Daewon Pharm
Administration: Oral

Overview

DW-330SR2 is an investigational drug evaluated in combination with pelubiprofen for the treatment of chronic back pain. It has been studied in a multicenter, randomized, double-blind, parallel, active-controlled Phase 3 clinical trial to assess its efficacy and safety in patients with chronic back pain. The specific mechanism of action and molecular target for DW-330SR2 are not detailed in the available sources. The developer associated with this compound is Daewon Pharmaceutical.

Other names: DW-330SR2DW330SR2DW 330SR2

Beyond the preview

Go deeper on DW-330SR2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW-330SR2.

Explore the full profile